ProQR Therapeutics N.V. - Ordinary Shares (PRQR) News
Filter PRQR News Items
PRQR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRQR News Highlights
- For PRQR, its 30 day story count is now at 10.
- Over the past 22 days, the trend for PRQR's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about PRQR are BEAT, DRUG and EYE.
Latest PRQR News From Around the Web
Below are the latest news stories about ProQR Therapeutics NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.
ProQR (PRQR) Reports Q4 Loss, Misses Revenue EstimatesProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial ResultsAdditional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; interim data readout from Helia extension study of ultevursen planned by year-end 2022Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and initial data from m |
Will ProQR (PRQR) Report Negative Q4 Earnings? What You Should KnowProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Why ProQR Therapeutics Stock Got Slammed Again MondayAnalysts are notably more bearish on the company following unhappy news about its leading drug candidate. |
ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III StudyProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study. |
Why ProQR Therapeutics Is Crashing TodaySepofarsen's failure to meet efficacy endpoints in the Illuminate trial isn't sitting well with investors. |
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus shamAdditional analyses to be conducted and presented at a future medical congressSepofarsen continues to be generally well toleratedStrong cash position provides runway into mid- to late-2024ProQR Management to host conference call today at 8:15am EST LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company |
Raymond James’ 2 Stock Picks With Over 70% Upside PotentialWhat can it all mean when mega-cap stocks and US Treasuries start behaving as if they were penny stocks? Tavis McCourt, Institutional Equity Strategist at Raymond James, has an idea about that. “We would argue it shows a complete lack of conviction by investors in certain business models/earnings power, and the state of the economy overall,” McCourt wrote. McCourt is talking of the spell of extreme volatility the markets are currently going through, noting that investors can’t make up their mind |
ProQR to Present at Upcoming SVB Leerink ConferenceLEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present at the upcoming virtual SVB Leerink 11th Annual Global Healthcare Conference. The presentation will be webcast live on February 17, 2022 from 1:40 – 2:05pm EST. Presentation and webcast details will b |
Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength?ProQR (PRQR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |